New Products

Recombinant Antigens for Influenza Vaccine Strains

The name "influenza" is derived from the Latin word for "influence," and the pathogens that cause this disease are RNA viruses from the family Orthomyxoviridae. Influenza virus is divided into four main types (Influenza A, Influenza B, Influenza C, Influenza D), epidemics of seasonal influenza occur due to influenza A or B viruses. Influenza global pandemics occurred and killed tens of millions of people, with each of these pandemics being caused by the appearance of a new strain of the virus in humans, such as A/California/04/09 (H1N1) and A/Hong Kong/1/1968 (H3N2).

Annual vaccination is the primary and most effective way to prevent influenza and influenza-associated complications, especially for high-risk groups. Vaccination can reduce illness and lessen severity of infection. Flu viruses are constantly changing, so the vaccine composition is reviewed each year and updated as needed based on which influenza viruses are making people sick, the extent to which those viruses are spreading, and how well the previous season’s vaccine protects against those viruses. In recent decades, Vaccines against the flu are trivalent or quadrivalent, providing protection against an H1N1 strain, an H3N2 strain, and one or two IBV strains corresponding to the two IBV lineages (Yamagata and Victoria type).

The development of influenza vaccine Fig. 1. The development of influenza vaccine

Creative Diagnostics offers recombinant antigens for influenza vaccine strains. The product line covers Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins, from all WHO-recommended vaccine strains in 2015-2022. The reagents can be used to analyze immune responses against vaccine antigens. Welcome to contact us if you are in need of influenza vaccine antigens.

2021-2022

A/Victoria/2570/2019 (H1N1) A/Wisconsin/588/2019 (H1N1)
Recommended for Egg-based (quadrivalent,trivalent) Vaccine Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: DAGC607, DAGC608 HA: DAGC607, DAGC608
NA: DAGC609 NA: DAGC609
NP: DAGC610 NP: DAGC610
B/Washington/02/2019 B/Phuket/3073/2013
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine
HA: DAGC611 HA: DAGC614
NA: DAGC612 NA: DAGC615
NP: DAGC613 NP: DAGC616
A/Cambodia/E0826360/2020 (H3N2)
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: DAGC617, DAGC618
NA: DAGC619
NP: DAGC620

2020-2021

A/Guangdong-Maonan/SWL1536/2019 (H1N1) A/Hong Kong/2671/2019 (H3N2)
Recommended for Egg-based (quadrivalent, trivalent) Vaccine Recommended for Egg-based (quadrivalent, trivalent) Vaccine
HA: DAGC621 HA: DAGC623
NP: DAGC622 NP: DAGC624
A/Hawaii/70/2019 (H1N1) A/Hong Kong/45/2019 (H3N2)
Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: DAGC621 HA: Under Development
NP: DAGC630 NP: DAGC631
B/Phuket/3073/2013 B/Washington/02/2019
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: DAGC614 HA: DAGC611
NA: DAGC615 NA: DAGC612
NP: DAGC616 NP: DAGC613

2019-2020

A/Brisbane/02/2018 (H1N1) A/Kansas/14/2017 (H3N2)
Recommended for Egg-based (quadrivalent) Vaccine Recommended for Egg-based (quadrivalent) Vaccine
HA: DAGC632 HA: DAGC635
NA: DAGC633 NA: DAGC636
NP: DAGC634 NP: DAGC637
B/Phuket/3073/2013 B/Colorado/06/2017
Recommended for Egg-based (quadrivalent) Vaccine Recommended for Egg-based (quadrivalent); trivalent Vaccine
HA: DAGC614 HA: DAGC274
NA: DAGC615 NP: Under Development
NP: DAGC616

2018-2019

A/Michigan/45/2015 (H1N1) A/Singapore/INFIMH-16-0019/2016 (H3N2)
Recommended for quadrivalent Vaccine Recommended for quadrivalent Vaccine
HA: DAGA-3986 HA: DAGA-3989
NA: DAGC638 NP: DAGC637
NP: DAGC639
B/Phuket/3073/2013 B/Colorado/06/2017
Recommended for quadrivalent Vaccine Recommended for quadrivalent; trivalent Vaccine
HA: DAGC614 HA: DAGC274
NA: DAGC615 NP: Under Development
NP: DAGC616

2017-2018

A/Michigan/45/2015 (H1N1) A/Hong Kong/4801/2014 (H3N2)
Recommended for trivalent Vaccine Recommended for trivalent Vaccine
HA: DAGA-3986 HA: DAGC640
NA: DAGC638 NA: DAGC641
NP: DAGC639 NP: DAGC642
B/Brisbane/60/2008 B/Phuket/3073/2013
Recommended for trivalent Vaccine Recommended for quadrivalent Vaccine
HA: DAG-H10320 HA: DAGC614
NA: DAGC644 NA: DAGC615
NP: Under Development NP: DAGC616

2016-2017

A/California/7/2009 (H1N1) A/Hong Kong/4801/2014 (H3N2)
Recommended for trivalent Vaccine Recommended for trivalent Vaccine
HA: DAG4439 HA: DAGC640
NP: DAGC646 NA: DAGC641
NP: DAGC642
B/Brisbane/60/2008 B/Phuket/3073/2013
Recommended for trivalent Vaccine Recommended for quadrivalent Vaccine
HA: DAG-H10320 HA: DAGC614
NA: DAGC644 NA: DAGC615
NP: Under Development NP: DAGC616

2015-2016

A/California/7/2009 (H1N1) A/Switzerland/9715293/2013 (H3N2)
Recommended for trivalent Vaccine Recommended for trivalent Vaccine
HA: DAGC645 HA: DAGC647
NP: DAGC646 NA: DAGC648
B/Brisbane/60/2008 B/Phuket/3073/2013
Recommended for quadrivalent Vaccine Recommended for trivalent Vaccine
HA: DAG-H10320 HA: DAGC614
NA: DAGC644 NA: DAGC615
NP: Under Development NP: DAGC616

References:

  1. Breen M, Nogales A, Baker SF, et al. Replication-Competent Influenza A Viruses Expressing Reporter Genes. Viruses. June 2016. 8(7):179.
  2. Dan D, Rebecca R, Henrik Ö, et al. Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. Frontiers in Immunology. July 2018. 9: 1581.
Inquiry Basket